Cannabis localization Europe projects usually begin with a product page. For CBD brands weighing a novel food route, however, the more demanding document is the dossier. On 18 September 2026, EFSA published a positive scientific opinion on synthetic CBD — cannabidiol obtained by chemical synthesis, with a purity of at least 98% w/w, dissolved in MCT oil, for use in food supplements. We read that as a signal, not as an authorisation. Brands that want to follow this route will have to describe purity, excluded consumer groups and a “provisional safe intake level” in every market language they use. Our thesis is simple: the wording needs market-specific validation before anyone translates it.
Cannabis Localization Europe Starts With the Dossier, Not the Label
The opinion concerns synthetic CBD at a purity of at least 98% w/w, dissolved in MCT oil, for use in food supplements at a maximum daily intake of 2 mg under the proposed conditions of use, for adults aged 25 and over. The proposed target population excludes pregnant and lactating women. EFSA could not establish the safety of the novel food for people taking medication. These details are drawn from the primary EFSA text (EFSA Journal 24(9):e10154). EFSA’s scientific opinion is not an authorisation to place the product on the EU market. Authorisation requires a separate decision under the EU novel food procedure. The status of the specific application should be confirmed against the European Commission’s records before publication.

Even so, the structure of the information matters for language work. In practice, a single dossier feeds several documents: the application itself, the product sheet, the label and the website copy. Each document repeats three key elements: purity, consumer exclusions and the intake figure. If a German label phrases an exclusion slightly differently from the French leaflet, a reviewer may read two different claims instead of one.
For instance, a regulatory affairs manager who inherits an English master dossier often receives translations produced at different times by different people. As a result, the same exclusion can appear in three versions. A cannabis translation workflow that starts from one validated source sentence per element, and then adapts it market by market, avoids that drift.
A “Provisional Safe Intake Level” Is Not an ADI
In its updated statement of 9 February 2026, EFSA introduced the term “provisional safe intake level” for CBD as a novel food. The September 2026 opinion on synthetic CBD applies that level to the specific application, concluding that the novel food is safe at a maximum daily intake of 2 mg under the proposed conditions of use. The acceptable daily intake, or ADI, is an established concept in food-safety assessment, and the two terms should not be treated as synonyms. Replacing one term with the other can change the regulatory meaning of the source text.
That temptation is real. Abbreviations such as “ADI” (or “IDA” in Spanish-language contexts) look familiar, and they fit neatly into a label. Nevertheless, familiar is not the same as correct. In our experience, the safer approach is to keep the original English term visible, add a short gloss, and ask qualified counsel in each target market whether a local rendering is acceptable.

Moreover, the same caution applies to the figure itself. Presenting the 2 mg daily intake as a consumer recommendation, a general dose limit or a legal ceiling would change its meaning. The figure belongs to the proposed conditions of use assessed by EFSA and should be labelled accordingly.
Consumer Exclusions Travel Badly Between Languages
Exclusions look simple, yet they are among the hardest sentences to localise. An age threshold such as “under 25” can be phrased in several ways, and the precise wording should follow the opinion, not a back-translation from news coverage. Likewise, “medication” in the source may be broad or narrow, and a translator needs the original context to choose between a general term and a specific one.
Before translation begins, record the approved wording for purity, consumer exclusions and the intake term in a shared glossary. Second, mark each term as “keep”, “gloss” or “validate locally”. Third, give the validated glossary to every person who touches the label, the product sheet and the website.
The question is not whether a sentence sounds natural in German or Dutch. It is whether the sentence preserves the same regulatory meaning that the source document carries. For specialist cannabis translation services across EU markets, visit our cannabis translation specialist services page.
What Cannabis Localization Europe Requires While the Process Is Open
At the time of writing, a positive scientific opinion does not by itself tell a brand what it may print on a label. We therefore suggest treating this moment as preparation time. Build the glossary, decide which terms stay untranslated, and identify the markets where you will need local legal review. The EFSA opinion does not, by itself, establish what a brand may legally place on a label. That assessment requires confirmation of the product’s authorisation status and the applicable food and labelling requirements in each target market. For a closer look at how novel food closures affect translation decisions, see our post on CBD novel food closures and what they mean for cannabis translation.
Done well, this preparation can make the later translation faster, and it helps protect consistency across cannabis localization Europe projects — a point we develop further in Cannabis Localization in Europe: 27 Regulatory Vocabularies. The open question for brand teams is practical: if your CBD dossier had to be published in five languages next month, who would own the decision on the intake term, and what would they check it against?
This article is for informational purposes only and does not constitute legal advice. Cannabis regulations change rapidly — verify current requirements with qualified legal counsel before making compliance decisions.
Sources
- EFSA NDA Panel (2026). Safety of synthetic cannabidiol as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 24(9), e10154. https://doi.org/10.2903/j.efsa.2026.10154 (open access via PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13586991/)
- FoodNavigator — EFSA gives positive opinion on CBD, 21 September 2026: https://www.foodnavigator.com/Article/2026/09/21/efsa-gives-positive-opinion-on-cbd/
- NutraIngredients — ‘Important turning point for CBD’ as EFSA publishes first positive safety opinion, 21 September 2026: https://www.nutraingredients.com/Article/2026/09/21/important-turning-point-for-cbd-as-efsa-publishes-first-positive-safety-opinion/

Comentarios recientes